Comprehensive genomic studies: Emerging regulatory, strategic, and quality assurance challenges for biorepositories

Sandra A. McDonald, Elaine R. Mardis, David Ota, Mark A. Watson, John D. Pfeifer, Jonathan M. Green

Research output: Contribution to journalReview article

8 Scopus citations

Abstract

As part of the molecular revolution sweeping medicine, comprehensive genomic studies are adding powerful dimensions to medical research. However, their power exposes new regulatory, strategic, and quality assurance challenges for biorepositories. A key issue is that unlike other research techniques commonly applied to banked specimens, nucleic acid sequencing, if sufficiently extensive, yields data that could identify a patient. This evolving paradigm renders the concepts of anonymized and anonymous specimens increasingly outdated. The challenges for biorepositories in this new era include refined consent processes and wording, selection and use of legacy specimens, quality assurance procedures, institutional documentation, data sharing, and interaction with institutional review boards. Given current trends, biorepositories should consider these issues now, even if they are not currently experiencing sample requests for genomic analysis. We summarize our current experiences and best practices at Washington University Medical School, St Louis, MO, our perceptions of emerging trends, and recommendations.

Original languageEnglish
Pages (from-to)31-41
Number of pages11
JournalAmerican journal of clinical pathology
Volume138
Issue number1
DOIs
StatePublished - Jul 1 2012

Keywords

  • Biobanks
  • Biorepositories
  • Genomic studies
  • Quality assurance
  • Regulatory standards

Fingerprint Dive into the research topics of 'Comprehensive genomic studies: Emerging regulatory, strategic, and quality assurance challenges for biorepositories'. Together they form a unique fingerprint.

  • Cite this